BACKGROUND Recent evidence suggests a role for hormonal factors in the aetiology of asthma.
METHODS Data from a large study of women selected from the general population were used to relate treatment with oral hormonal contraceptives (OCP) and postmenopausal hormone replacement therapy (HRT) to the following asthma indicators: self-reported asthma, wheezing, cough at exertion, and use of medication for asthma. The study sample comprised 1536 premenopausal and 3016 postmenopausal women who participated in the third round of the Copenhagen City Heart Study in 1991–4. A total of 377 women were taking OCP (24.5% of premenopausal women) and 458 were on HRT (15.2% of postmenopausal women).
RESULTS In premenopausal women 4.8% reported having asthma. The prevalence of self-reported asthma, wheeze, use of asthma medication, and cough at exertion was not significantly related to use of OCP. In postmenopausal women the prevalence of self-reported asthma was 6.2%. A weak but consistent association was observed between HRT and self-reported asthma (OR 1.42 (95% CI 0.95 to 2.12)), wheeze (OR 1.29 (95% CI 1.02 to 1.64)), cough at exertion (OR 1.34 (95% CI 1.01 to 1.77)), and use of asthma medication (OR 1.45 (95% CI 0.97 to 2.18)).
CONCLUSIONS In this study of the general population no relationship was found between the use of OCP and asthma. Although an association was observed between HRT and asthma and asthma-like symptoms, this was relatively weak and it is concluded that there is no necessity to change present prescription practice.
- hormone replacement therapy
- oral contraceptives
- female sex steroid hormones
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The prevalence of asthma has drawn considerable attention during recent years, primarily because it appears to be increasing in many countries.1 ,2 Different mechanisms responsible for this increase have been postulated. Most studies of adults show that asthma and hospital admissions for asthma are more prevalent in women than in men, which may suggest that asthma is more severe in women than in men.3-5 The severity of asthma in some women varies during the menstrual cycle, and disease severity is also affected by pregnancy. Furthermore, since up to 30% of women take exogenous oestrogens alone or together with progesterone, hormonal factors have been suggested as modifiers of asthma severity.6 As treatment with sex hormones may increase disease severity in some asthmatic women, it may also be reflected by an increased prevalence of asthma symptoms and use of asthma medication in women on this treatment. In keeping with this, Troisi and co-workers reported a significant association between treatment with sex hormones and adult onset asthma in an epidemiological study of more than 100 000 nurses in the USA.7 Yet, in a recent survey of 461 women with asthma recruited from general practice, Forbes et al did not observe an increase in asthma severity in women on oral hormonal contraceptives (OCP).8
The purpose of the present investigation was to analyse the prevalence of asthma in relation to treatment with exogenous sex hormones in women randomly selected from the general population. We used data from the third examination round of the Copenhagen City Heart Study comprising 4552 women living in the city of Copenhagen and related treatment with OCP and postmenopausal hormonal replacement therapy (HRT) to self-reported asthma, asthma symptoms, and use of medication for asthma.
All the women included in the present analyses participated in the third round of the Copenhagen City Heart Study, a prospective epidemiological cardiopulmonary study initially started in 1976.9 The original population sample was drawn in January 1976 from the Copenhagen population register of a population of approximately 90 000 inhabitants aged 20 years or more. The sample was age stratified with the main emphasis being placed on those aged 35–70 years. The cohort was investigated for the first time in 1976–8, for the second time in 1981–3, and for the third time in 1991–4. At the third examination the cohort consisted of the subjects that had been included in previous investigations and an additional sample of 3000 subjects aged 20–39 years. A total of 5685 women and 4450 men participated in this examination (response rate 61.2%). In general, the response rates were highest among subjects aged 40–70 years (68–80%) and lowest among those aged 80 years or more (28–41%). Previous investigations of non-responders performed at the first examination showed that the prevalence of asthma in the non-responders investigated in their homes was slightly higher than in the responders.10
After excluding 440 women with incomplete data required for the present analyses, the final study sample comprised 1536 premenopausal and 3016 postmenopausal women. Information on hormonal treatment was obtained from the questionnaire. The women were classified as premenopausal or postmenopausal on the basis of the questionnaire according to whether they were still menstruating or had entered the menopause; they also reported whether or not they were taking OCP or HRT. No details were obtained concerning the type of sex hormones being taken.
Based on the information from the questionnaire, the following asthma indicators were investigated:
Self-reported asthma (an affirmative answer to the question “Do you have asthma?”)
Use of asthma medication
Cough at exertion
In addition to cross tabulation of these asthma indicators in relation to the use of exogenous hormones, several multiple logistic regression analyses were performed with each of the asthma indicators as the dependent variable, use of hormones as the independent variable of interest, and age, length of school education, body mass index (BMI), smoking, and familiar predisposition to asthma as covariates. Separate analyses were performed on use of OCP in premenopausal women and on HRT in postmenopausal women. All reported p values are based on two sided tests of significance and a p value of <0.05 was considered significant. The possible interactions between different variables were assessed using the log likelihood test.
A total of 377 women were on OCP (24.5% of premenopausal women) and 458 were on HRT (15.2% of postmenopausal women). The age span of premenopausal women was 21–49 years and of postmenopausal women was 27–90 years. The general characteristics of women taking and not taking exogenous sex hormones are shown in table 1. In both premenopausal and postmenopausal women those taking sex hormones were younger; the remaining characteristics differed very little.
The prevalence of the chosen asthma indicators in premenopausal women according to treatment with OCP is shown in table 2. None of the asthma indicators was more prevalent in the subgroup on hormonal contraception. Stratification of the women according to smoking habits did not change the results. Similarly, no significant association between any asthma indicator and OCP was seen when using multiple logistic regression with age, length of school education, BMI, and smoking as covariates (not shown).
In postmenopausal women preliminary analyses suggested differences in smoking subgroups and therefore the results are presented separately for never smokers, ex-smokers, and smokers (table 3). In most of the comparisons the asthma indicators were not significantly more prevalent in the women on HRT. However, in never smokers there was a higher prevalence of self-reported asthma and asthma medication in those on HRT (table 3).
The results of multiple logistic regression of the effects of HRT and smoking on asthma indicators in postmenopausal women together with various covariates are shown in table 4. The odds ratios (ORs) for all four asthma indicators were higher in women on HRT with p values of approximately 0.05 and confidence intervals close to 1 (table 4). As expected, the ORs were higher in women with familial predisposition to asthma and short school education. A high BMI was significantly related to wheezing but not to the remaining asthma indicators. Smoking was strongly related to all asthma indicators.
Because of the trends observed in table 3, additional analyses were performed to explore the possible interaction between HRT and smoking on asthma indicators. A borderline interaction (p=0.03) was found which showed that HRT was associated with a much higher risk of asthma in never smokers (OR 3.3 (95% CI 1.6 to 7.1)) than in current smokers (OR 1.2 (95% CI 0.7 to 2.1). A similar interaction (p=0.05) was observed for asthma medication but not for wheezing and cough at exertion.
In this study of women selected from the general population, we could not demonstrate any significant association between OCP and asthma, use of asthma medication, and asthma related symptoms. A relatively weak association was detected with HRT, suggesting that postmenopausal women on HRT have a slightly higher risk of asthma and asthma-like symptoms. The size of the population makes it unlikely that important negative effects of exogenous female sex hormones on asthma were undetected.
With regard to OCP, our results are clear and reassuring. Oral contraceptive pills reduce the dynamic fluctuations in oestrogen and progesterone levels over the menstrual cycle and, given that these cyclic changes cause changes in asthma severity, OCP might reduce their amplitude and thus make asthma more stable. This assumption is in line with most previous reports which have shown that OCP may reduce airway responsiveness, peak flow variability, and perceived severity of asthma.11 ,12 These findings are, however, not uniform and observations from a few small studies have even suggested that administration of exogenous sex hormones to premenopausal women may make asthma worse.13-15 However, a recent general practice based study of asthmatic women by Forbeset al found no significant differences in asthma quality of life scores between women on OCP and those not taking exogenous hormones.8 Furthermore, only 4% of the participants reported worsening of their asthma due to the hormonal contraceptives, and these women had significantly worse asthma than the remaining group of participants. This study therefore suggests that, at least in women with relatively mild asthma, oral hormonal contraceptives do not have a pronounced influence on symptom severity. Although our approach differs by looking at a sample of the general population, a lack of association between OCP and asthma and asthma-like symptoms is in keeping with the findings of Forbeset al.8
Postmenopausal women have very limited fluctuations in endogenous sex hormones which, at least theoretically, makes it less likely that HRT would have a substantial impact on asthma symptoms.6However, oestrogen enhances the production of corticosteroid binding globulin and progesterone competes with cortisol for binding sites. Thus, both oestrogen and progesterone may influence the level of free cortisol, leading to decreased levels. Furthermore, it has previously been hypothesised that oestrogen may induce resistance to cortisol in both peripheral tissues and the central nervous system. However, in line with these contradictory theoretical considerations, both smaller clinical studies and case studies of the influence of HRT on asthma severity have reported conflicting observations, some showing remarkable improvement in symptoms and others a pronounced worsening.16-19 Sex steroid hormones may play a role in the expression of asthma in susceptible individuals, but the only available epidemiological evidence for an association between HRT and adult onset asthma comes from the Nurses' Health Study7which showed not only that oestrogen is likely to play a role in the pathophysiology of asthma, but also that long term use and/or high doses of postmenopausal HRT significantly increased the risk for subsequent development of asthma. Although our cross sectional findings of a weak association between HRT and asthma indicators support the hypothesis of a deleterious effect of exogenous female sex hormones on asthma, the association was weak. After stratification for smoking habits, the strongest association was seen between asthma/asthma medication and HRT in never smokers. However, we did not observe a clear increase in asthma symptoms (wheeze and cough) in this smoking subgroup (table 3). The most likely explanation for this discrepancy is that postmenopausal women on HRT are more likely to visit their GPs than women not on HRT and, if they are never smokers, they more likely to have their respiratory symptoms diagnosed as asthma and to receive asthma medication. Another possible explanation is that, because of the strong influence of smoking on asthma-like symptoms, a potential association between HRT and asthma is only detectable in non-smokers. A third possible explanation for the interaction between HRT and smoking in asthma is that the deleterious effect of HRT is counteracted by the anti-oestrogenic effect of smoking. Although these explanations are speculative at present, previous studies have suggested that smoking may exert an anti-oestrogenic effect by altering the metabolism of endogenous and exogenous sex hormones.20 ,21 Finally, although self-reported asthma has been shown to be a valid indicator of asthma in epidemiological settings,22 some degree of misclassification in postmenopausal women has probably occurred in our study with some subjects with mild asthma remaining undiagnosed and others with chronic obstructive pulmonary disease being diagnosed as asthmatics.
We conclude that there is no relationship between the use of oral hormonal contraceptives and asthma and asthma-like symptoms in the general population, while HRT after the menopause seems to be associated with a slightly higher risk of asthma. However, since this association was relatively weak, we think that further studies are needed and that present prescription policies in postmenopausal women do not yet need to be changed.
This study was supported by grants from The Danish Lung Association, The Danish Heart Foundation and The Danish Medical Research Council.